Stephens Inc. AR Sells 500 Shares of Edwards Lifesciences Corporation

Edwards Lifesciences Corp (NYSE:EW) has risen 15.41% since June 15, 2016 and is uptrending. It has outperformed by 12.37% the S&P500.

Netols Asset Management Inc increased its stake in Trimas Corp (TRS) by 12.73% based on its latest 2016Q4 regulatory filing with the SEC. ETRADE Capital Management LLC now owns 3,720 shares of the medical research company's stock worth $449,000 after buying an additional 349 shares during the last quarter. State Board of Administration of Florida Retirement System now owns 14,266 shares of the life sciences company's stock worth $1,224,000 after buying an additional 240 shares in the last quarter. About 204,524 shares traded. TriMas Corp (NASDAQ:TRS) has risen 34.96% since June 14, 2016 and is uptrending. It has outperformed by 40.38% the S&P500.

Another recent and important Edwards Lifesciences Corp (NYSE:EW) news was published by which published an article titled: "Why Is Edwards Lifesciences (EW) Up 4.5% Since the Last Earnings Report?" on May 26, 2017. A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range. Therefore 72% are positive. Northland Securities set a $105.00 target price on Edwards Lifesciences Corporation and gave the company a buy rating in a research note on Monday, March 20th. The stock now has an average rating of "Buy" and an average target price of $120.38. As per Thursday, January 21, the company rating was upgraded by Suntrust Robinson. Canaccord Genuity maintained Edwards Lifesciences Corp (NYSE:EW) rating on Wednesday, February 3. Edwards Lifesciences Corporation presently has a consensus rating of "Buy" and an average target price of $120.38. The stock of Edwards Lifesciences Corp (NYSE:EW) has "Sell" rating given on Wednesday, July 27 by Citigroup. Equities analysts expect that Edwards Lifesciences Corporation will post $3.53 earnings per share for the current year. As per Wednesday, October 26, the company rating was maintained by RBC Capital Markets.

Investors sentiment decreased to 1.13 in Q4 2016. Its down 0.01, from 0.95 in 2016Q3. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $48.00 target price (up previously from $46.00) on shares of Integra LifeSciences Holdings Corporation in a report on Tuesday, May 2nd.

Several hedge funds have recently added to or reduced their stakes in the company. Texas Permanent School Fund has invested 0.02% of its portfolio in Integra Lifesciences Holdings Corp (NASDAQ:IART). One investment analyst has rated the stock with a sell rating, six have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. De Burlo holds 6,027 shares. Riverhead Mngmt holds 0.42% in McKesson Corporation (NYSE:MCK) or 49,035 shares. Tiaa Cref Management Ltd Co accumulated 0% or 138,006 shares. Principal Financial Group Inc stated it has 4.78M shares or 0.26% of all its holdings. Invesco Limited owns 800,117 shares for 0.02% of their portfolio. The Bank is a chartered commercial bank. State Board Of Administration Of Florida Retirement reported 0% in Integra Lifesciences Holdings Corp (NASDAQ:IART). UBS initiated Edwards Lifesciences Corp (NYSE:EW) on Tuesday, September 22 with "Buy" rating. The company has market cap of $24.07 billion. The Firm focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. It has a 37.99 P/E ratio. The Company's divisions include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue fix and tissue regeneration products, and small bone fixation and joint replacement solutions. Edwards Lifesciences Corp had 61 analyst reports since July 30, 2015 according to SRatingsIntel. During the same period in the previous year, the business earned $0.71 earnings per share. EW's profit will be $184.56 million for 32.61 P/E if the $0.88 EPS becomes a reality. The medical research company reported $0.94 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.82 by $0.12. It also upped Eaton Corp Plc (NYSE:ETN) stake by 24,932 shares and now owns 94,524 shares. Ishares Msci (EPU) was reduced too. A rating of 4 or 5 would indicate a consensus Sell. Therefore 50% are positive. The firm has "Equalweight" rating by Barclays Capital given on Thursday, June 2. On Friday, January 6 the stock rating was upgraded by JMP Securities to "Mkt Outperform". Liberum Capital reinitiated the stock with "Hold" rating in Monday, March 27 report. The company was maintained on Wednesday, August 19 by Telsey Advisory Group. The stock of Edwards Lifesciences Corp (NYSE:EW) earned "Neutral" rating by Guggenheim on Thursday, June 9. The stock has "Outperform" rating by Bernstein on Monday, August 22.

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with our FREE daily email newsletter.

Latest News